StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Strong FCF and continued buybacks support per-share value; stable volumes reduce downside risk absent policy shocks. One-time impairment in China is non-cash and isolated; 2026 guidance provides a clear framework for investors.
What happened, with direct paths to the underlying reporting
DaVita reported Q3 2026 results with revenue of $3.58B and adjusted EPS of $3.82, supported by strong operating cash flow of $519M and free cash flow of $276M. The firm executed 0.6M share repurchases at $186.21 and added 0.5M post-quarter, signaling continued capital allocation discipline. While US dialysis volumes were largely flat, a $62M China impairment reduced net income by about $27M after tax, but guidance remains intact for 2026 adj operating income and free cash flow targets.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.